The latest headlines across every section, pulled from official and open-access sources.
As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog, petrelintide.
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.
When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.
Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.
Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.
With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies.
Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.”
As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now.
As costs climb, capital tightens and AI enthusiasm accelerates, biopharma leaders are rethinking how better decisions get made.
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers.
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”
In this interview, Alison L. Bailey, MD, FACC and Aaron Baggish, MD, FACC examine the latest sports cardiology guidelines.
Galmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion.
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.
The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2—India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...
The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes)...
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key late-phase program and continues the “bumpy ride” for Sanofi’s pipeline.
Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history.
Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across multiple disease areas.”
Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma.